A new anthraquinone derivative, the small-molecule TC-19 (N19), has received a US patent as an inhibitor of cell proliferation in NSCLC cells (NSC777201) and it has also shown effective inhibition of cell growth in DU-145 and PC-3 cell lines.23 In this study, we provide new evidence that N19 may act as a dual inhibitor of both EGFR and cMET against PXN-mediated EGFR-TKI resistance in NSCLC cells and that it acts by promoting the degradation of both proteins by ubiquitin proteasomes. The gene discussed is PXN; the disease is non-small cell lung carcinoma.